AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05050981
Drug: Selective serotonin reuptake inhibitors
RxNorm normalized name: Selective serotonin reuptake inhibitors
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective serotonin reuptake inhibitors: anyone in the category, e.g.: fluoxetine, sertraline, etc.
Trial: NCT04167618
Drug: 177Lu-DTPA-omburtamab
RxNorm normalized name: DTPA
DrugBank: Omburtamab (DB15635)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological, radiolabeled DPTA-omburtamab
Trial: NCT06015022
Drug: Epigallocatechin gallate (EGCG)
DrugBank: Epigallocatechin gallate (DB12116)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGCG is a green tea-derived catechin
Trial: NCT05690035
Drug: Tislelizumab & Fruquintinib
DrugBank: Fruquintinib (DB11679)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combinational treatment of Tislelizumab and Fruquintinib until PD, intolerable toxicity, death or withdrawal of informed consent
Trial: NCT06679569
Drug: rocuronium 0.6 mg/kg/hr continuous infusion
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To maintain Train-of-four count 0 during surgery: Administration of continuous infusion of rocuronium at a rate of 0.6 mg/kg/hr to achieve and sustain deep neuromuscular blockade.
Trial: NCT05884255
Drug: Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lutetium (177Lu) Oxodotreotide Injection combined with standard-dose long-acting Octreotide
Trial: NCT05884255
Drug: long-acting Octreotide.
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: High-dose long-acting Octreotide.
Trial: NCT05312476
Drug: Chimeric Antigen Receptor T Cells (CAR-T) Targeting Igβ Targets
RxNorm normalized name: Autologous bi-epitope BCMA-targeted CAR T-cells
DrugBank: Ciltacabtagene autoleucel (DB16738)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Dose escalation studies:3 dose groups in total: expect 3-6 cases in each group, and dose set at 1×106/kg，3×106/kg，6×106/kg.~2. Dose extension study:3 cases (1 dose group).
Trial: NCT05202288
Drug: Inmazeb
RxNorm normalized name: Inmazeb
DrugBank: Atoltivimab (DB15898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of Inmazeb
Trial: NCT06677827
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: External Oblique Intercostal plane block technique with 20 ml bupivacaine 0.25% only bilateral
Trial: NCT06677827
Drug: Magnesium Sulfate and Bupivacaine 0.125%
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: External Oblique Intercostal plane block technique with 20 ml bupivacaine 0.25%+200 mg magnesium sulphate bilateral
Trial: NCT05429489
Drug: Intravenous morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous morphine 0.1 mg/kg
Trial: NCT05886257
Drug: Candonilimab
RxNorm normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg/kg, iv.drip, every 3 week
Trial: NCT05886257
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 15mg/kg, iv.drip, every 3 week
Trial: NCT06151938
Drug: Standardised allergen extract from house dust mites
RxNorm normalized name: European house dust mite allergenic extract
DrugBank: House dust (DB10345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Allergen immunotherapy \[ACARIZAX® (12-SQ HDM) house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet\] for moderate to severe house dust mite allergic rhinitis with or without allergic asthma for 12 months.
Trial: NCT06049745
Drug: Misoprostol 400 Microgram Oral Tablet
RxNorm normalized name: Misoprostol 400 microgram oral tablet
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: S.L misoprostol 400 mcg
Trial: NCT06435832
Drug: Absorbable Gelatin
RxNorm normalized name: Absorbable gelatin film
DrugBank: Gelatin (DB11242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After tooth extraction, only saline irrigation was applied and a absorbable gelatin sponge was placed in the socket.
Trial: NCT06435832
Drug: Chlorhexidine
RxNorm normalized name: Chlorhexidine
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After tooth extraction, after irrigation with saline, 2% chlorhexidine gel was absorbed into gelatin sponges and placed into the socket.
Trial: NCT06435832
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid 50mg/ml for injection after saline irrigation after tooth extraction solution into gelatin sponges was applied to the socket after it was cured.
Trial: NCT05683782
Drug: Split thickness Apically positioned flap with Chitosan based Erythropoietin Gel application
RxNorm normalized name: Chitosan
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split thickness Apically positioned flap will be performed to increase width of attached gingiva .1 mL of EPO-loaded with chitosan 5% and β-glycerophosphate disodium salt (GP) 20% gel will be used by the patient two times daily for 14 days.
Trial: NCT05683782
Drug: Split thickness Apically positioned flap without Erythropoietin application
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split thickness Apically positioned flap will be performed to increase width of attached gingiva.The patient will use a Chitosan gel without being loaded with erythropoietin two times daily for 14 days
Trial: NCT06606327
Drug: Diazoxide, 3 mg/kg per dose
DrugBank: Diazoxide (DB01119)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin anti-secretagogue taken for 8 doses over 4 days
Trial: NCT04540692
Drug: Docetaxel or Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Treatment will start with Docetaxel 75-100mg/m² intravenously every 21 days for 4 cycles or weekly paclitaxel 80mg/m² for 12 weeks
Trial: NCT05444543
Drug: Fluticasone Propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will cycle topical steroid in a three-months on three-months off fashion
Trial: NCT05444543
Drug: Budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will cycle topical steroid in a three-months on three-months off fashion
Trial: NCT05368558
Drug: Cariprazine
RxNorm normalized name: Cariprazine
DrugBank: Cariprazine (DB06016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Capsule
Trial: NCT04952467
Drug: 14C-XEN1101
RxNorm normalized name: urea [14C]
DrugBank: Urea C-13 (DB09510)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects will receive a single oral administration of a capsule containing 20 mg XEN1101
Trial: NCT04614584
Drug: Mirtazapine
RxNorm normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mirtazapine 30 mg PO daily x 4 days
Trial: NCT04614584
Drug: Methamphetamine
RxNorm normalized name: Methamphetamine
DrugBank: Metamfetamine (DB01577)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methamphetamine 30 mg IV once
Trial: NCT06602492
Drug: Lower nicotine e-liquid
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A 3% nicotine concentration eliquid.
Trial: NCT06602492
Drug: Higher nicotine eliquid
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A 5% nicotine concentration eliquid.
Trial: NCT05694130
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Tacrolimus 1-2mg twice daily for 12 weeks.
Trial: NCT05467826
Drug: Sofosbuvir/Velpatasvir + Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sofosbuvir 400mg/velpatasvir 100mg + ribavirin 1000mg/1200mg for 12 weeks
Trial: NCT05467826
Drug: Sofosbuvir/Velpatasvir/Voxilaprevir
RxNorm normalized name: sofosbuvir/velpatasvir/voxilaprevir
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sofosbuvir 400mg/velpatasvir 100mg/voxilaprevir 100mg for 12 weeks
Trial: NCT05822674
Drug: Sitagliptin/metformin ( 50/500mg) Oral Tablet
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The drug was prescribed once daily per oral for 10 weeks
Trial: NCT05822674
Drug: Empagliflozin/metformin(10/500mg) Oral Tablet
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The drug was prescribed once daily per oral for 10 weeks
Trial: NCT06474481
Drug: Zanubrutinib
RxNorm normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zanubrutinib, 160mg PO BID.on days 1-28 Induction treatment: 4-6cycles ; Maintenance: 1 year;
Trial: NCT06474481
Drug: Obinutuzumab
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Induction treatment: Obinutuzumab (G), 1000mg, IV, D1/8/15 (C1), D1 (C2-4/6); for 4-6 cycles, 1 cycle = 28 days Maintenance: Obinutuzumab (G), 1000mg, IV, every 2 months for 1 year;
Trial: NCT06474481
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone (P), 100 mg, PO, D2-6；for 4-6 cycles for CHOP treatment , 1 cycle = 28 days
Trial: NCT06474481
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vincristine (O), 1.4 mg/m2 (maximum 2 mg), IV, D2; for 4-6 cycles for CHOP treatment , 1 cycle = 28 days
Trial: NCT06190886
Drug: PTX-912
RxNorm normalized name: PTX-100
DrugBank: PTX-100 (DB18125)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigation Product Monotherapy
Trial: NCT06551129
Drug: Mavacamten
RxNorm normalized name: Mavacamten
DrugBank: Mavacamten (DB14921)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: As prescribed by treating physician
Trial: NCT05268419
Drug: Water Distilled
RxNorm normalized name: petroleum distillate
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of water distilled spray
Trial: NCT05965817
Drug: SGM-101 op top of ICG
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SGM-101 op top of ICG
Trial: NCT06210945
Drug: 10 mg/kg CM-101
DrugBank: CM-101 (DB18293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg CM-101
Trial: NCT06204016
Drug: Estradiol Valerate
RxNorm normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To elevate estradiol levels each woman will receive 12mg on two consecutive days (total 24mg) of estradiol valerate (Progynova21©)
Trial: NCT06616961
Drug: Semaglutide Pen
RxNorm normalized name: semaglutide Pen Injector
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: In this study, the intervention involves administering semaglutide (Fitaro) to participants for weight management. The treatment protocol includes the following steps:~Initial Dose: Participants will start with a subcutaneous injection of semaglutide at a dose of 0.25 mg once weekly for the first four weeks to allow for tolerance and adjustment.~Dose Escalation: After the initial period, the dose will be increased at four-week intervals as follows:~Week 5: Increase to 0.5 mg Week 9: Increase to 1 mg Week 13: Increase to 1.7 mg Week 17: Increase to a maximum dose of 2.4 mg, if necessary, based on individual weight loss response and tolerability.
Trial: NCT06606886
Drug: Tablet Metformin (Group A)
RxNorm normalized name: metformin Oral Tablet
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablet Metformin 500 mg/dose orally twice a day with meal for 1 year
Trial: NCT06608433
Drug: semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: semaglutide/Rybelsus will be administered as a single oral dose
Trial: NCT05247268
Drug: Megestrol Acetate 160 MG Oral Tablet
RxNorm normalized name: megestrol acetate 160 MG Oral Tablet
DrugBank: Megestrol acetate (DB00351)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: At a dosage of 160 mg/day
Trial: NCT05247268
Drug: Medroxyprogesterone Acetate 500 MG
RxNorm normalized name: medroxyprogesterone acetate 500 MG
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: At a dosage of 500 mg/day
Trial: NCT05247268
Drug: Triprorelin Acetate
RxNorm normalized name: triptorelin acetate
DrugBank: Triptorelin (DB06825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of 3.75mg was given 4 weeks apart and the maximum use are 6 courses
Trial: NCT05247268
Drug: Letrozole 2.5mg
RxNorm normalized name: LETROZOLE 2.5MG TAB
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: At a dosage of 2.5mg/day and no more than 24 weeks
Trial: NCT05258851
Drug: Ceftazidime-avibactam
RxNorm normalized name: avibactam
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Experimental
Trial: NCT05258851
Drug: Colistin
RxNorm normalized name: Colistin
DrugBank: Colistin (DB00803)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control
Trial: NCT06676449
Drug: chemotherapy: Paclitaxel/Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paclitaxel 135mg/m2 d1, cisplatin 25mg/m2 d1-3, once every 3 weeks for 4 cycles.
Trial: NCT06285240
Drug: Donepezil
RxNorm normalized name: Donepezil
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg oral tablets
Trial: NCT06015113
Drug: Disitamab Vedotin plus pyrotinib or naratinib
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Pyrotinib (DB14993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Trastuzumab Injection: Intravenous infusion, initial loading dose of 2 mg/kg, administered via intravenous infusion over 30-90 minutes (usually recommended around 60 minutes), administered on day 1 of each cycle, with each cycle lasting 14 days.~Pyrotinib Maleate Tablets: 400 mg, taken orally once daily, within 30 minutes after a meal, at the same time every day. Taken continuously, with each cycle lasting 14 days.~Neratinib Maleate Tablets: 240 mg, taken orally once daily with a meal, at the same time every day. The neratinib tablet should be swallowed whole (it should not be chewed, crushed, or split before swallowing). Taken continuously, with each cycle lasting 14 days.
Trial: NCT05298592
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT05298592
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT05298592
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT00022841
Drug: Pamidronate
RxNorm normalized name: Pamidronate
DrugBank: Pamidronic acid (DB00282)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04934852
Drug: Ephedrine
RxNorm normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: When elderly patients had hypotension (invasive blood pressure drops \>20% from the baseline value or \<100 mmHg, or MAP \<70mmHg) 20 minutes after anesthesia induction, 4 mg ephedrine in 10 ml saline was usd Intravenously
Trial: NCT04934852
Drug: Ephedrine
RxNorm normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: When elderly patients had hypotension (invasive blood pressure drops \>20% from the baseline value or \<100 mmHg, or MAP \<70mmHg) 20 minutes after anesthesia induction, 8 mg ephedrine in 10 ml saline was usd Intravenously
Trial: NCT04934852
Drug: Ephedrine
RxNorm normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: When elderly patients had hypotension (invasive blood pressure drops \>20% from the baseline value or \<100 mmHg, or MAP \<70mmHg) 20 minutes after anesthesia induction, 12 mg ephedrine in 10 ml saline was usd Intravenously
Trial: NCT06531915
Drug: Ciprofol
RxNorm normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in the ciprofol group will be intravenously injected with 0.4 mg/kg of ciprofol (batch number H20200013, Haisike Pharmaceutical Co., Ltd., Liaoning, China) and sufentanil (0.2 μg/kg).
Trial: NCT06531915
Drug: Remimazolam
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants in the remimazolam group will be intravenously injected with 0.1 mg/kg of remimazolam besylate (batch number HR7056, Hengrui Pharmaceutical Co., Ltd., Jiangsu, China) and sufentanil (0.2 μg/kg).
Trial: NCT05155527
Drug: Ivermectin Tablets
RxNorm normalized name: Ivermectin Tablets
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6 mg/tablet
Trial: NCT06679465
Drug: Tiotropium (Spiriva®)
RxNorm normalized name: tiotropium Inhalation Powder [Spiriva]
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 puffs tiotropium prior to allergen challenge
Trial: NCT05753813
Drug: Phexxi
RxNorm normalized name: Phexxi
DrugBank: Citric acid (DB04272)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravaginal gel twice weekly for 4 weeks.
Trial: NCT06106334
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered as oral capsules
Trial: NCT04855591
Drug: SHR-1703
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-1703 will be administered subcutaneously
Trial: NCT04792489
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lymphodepleting chemotherapy
Trial: NCT04792489
Drug: Bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lymphodepleting chemotherapy
Trial: NCT06120530
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraperitoneal Bupivicaine without epinephrine 30 mg administered following completion of pelvic organ prolapse repair.
Trial: NCT04783194
Drug: Dexamethasone+ Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dexamethasone plus bupivacaine in bilateral trans-incisional paravertebral block in lumbar spine surgery.
Trial: NCT04783194
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacaine in bilateral trans-incisional paravertebral block in lumbar spine surgery.
Trial: NCT05360511
Drug: particulate xenograft + erythropoietin gel.
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Surgical sites will be anaesthetized using local anaesthesia.~2. Intrasulcular incision will be done in the periodontal pocket as close as possible to the tooth surface with the deepest point being the alveolar crest.~3. The incisions will be extended to the mesial papilla of the tooth before the defect and the distal papilla of the tooth after the defect.~4. Both buccal and lingual/palatal mucoperiosteal flaps will be raised using blunt dissection.~5. Mechanical debridement of the infected tissue from the intrabony defect and root debridement will be done using Gracey curettes.~   * In Group A (test group):~Particulate xenograft will be mixed with EPO gel and applied to fill the whole defect.
Trial: NCT05283330
Drug: ²¹²Pb-DOTAM-GRPR1
RxNorm normalized name: DOTA-TATE
DrugBank: Dotatate (DB14554)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ²¹²Pb-DOTAM-GRPR1 is a radioimmunoconjugate comprised of ²¹²Pb, the metal chelator DOTAM (1,4,7,10-Tetrakis(carbamoylmethyl)-1,4,7,10- tetraazacyclododecane) and a GRPR-targeted antagonist.
Trial: NCT05600023
Drug: Nitrofurantoin
RxNorm normalized name: Nitrofurantoin
DrugBank: Nitrofurantoin (DB00698)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitrofurantoin has been found to successfully eradicate gram-negative bacteria such as Enterococcus faecalis that one of the most important bacteria in endodontic lesions
Trial: NCT05600023
Drug: Double Antibiotic
RxNorm normalized name: Double Antibiotic
DrugBank: Bacitracin (DB00626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DAP is a combination of two antibiotics which are ciprofloxacin and metronidazole
Trial: NCT05248945
Drug: Evobrutinib
RxNorm normalized name: Evobrutinib
DrugBank: Evobrutinib (DB15170)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single dose of film-coated evobrutinib tablet (TF2) on Day 1 and Day 19.
Trial: NCT05248945
Drug: Carbamazepine
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive carbamazepine tablet twice daily from Days 2 to 25.
Trial: NCT05661461
Drug: nab-sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: This is a phase 1, multi-center, open-label, dose-escalation study of nab-sirolimus in adult patients with locally advanced or metastatic solid tumors and moderate hepatic impairment or normal hepatic function.
Trial: NCT04819373
Drug: BDB001
RxNorm normalized name: BDB001
DrugBank: BDB-001 (DB16480)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDB001 is an immunotherapy agent.
Trial: NCT05587257
Drug: Niosome minoxidil
RxNorm normalized name: Minoxidil
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patient of alopecia areata will be treated by topical nanominoxidil preparation twice daily for 3 months with no other treatment.